Epitherapeutics raises DKK 10 M in an extended seed financing

Epitherapeutics, a biopharmaceutical company making innovative pharmaceutical agents based on its discoveries and leading scientific position in the field of epigenetics, announced today the participation of Life Science Investments (the venture arm of the Lundbeck Foundation/LFI) in its seed round, bringing the total seed financing to DKK 34 M. LFI Life Science Investments joins an investor group that includes Novo Seeds and Seed Capital. Coincident with the extension of the seed round, Mette Kirstine Agger, Executive Director and Head of LFI Life Science Investments, joins the Company’s Board of Directors.

The new financing will support the further drug discovery efforts at Epitherapeutics and will fuel the work on building a pipeline of novel small-molecule inhibitors against selected epigenetic targets with a primary focus on oncology. The discovery of such inhibitors is done in close collaboration with Prof. Kristian Helin’s laboratory at BRIC, University of Copenhagen. Prof. Helin, a co-founder of Epitherapeutics, is a world leader in the field of basic oncology research and involved in the discovery of various epigenetic enzymes and their role in human diseases, including oncology.

For further information, please contact:

Martin Bonde
CEO
E-mail: mb@epitherapeutics.dk
Mobile: (+45) 20 25 35 60

Or visit: www.epitherapeutics.dk/